MPs Urge NHS to Expand Weight-Loss Jab Access Beyond Current 6% Target
A cross-party committee of MPs has called for a substantial increase in access to new weight-loss medications on the NHS, arguing that current plans are overly restrictive.
The Health and Social Care Committee stated that the NHS's ambition to provide the drug Mounjaro to only 6% of eligible patients by 2028 is insufficient. This target, established by NHS England, translates to approximately 50,000 individuals receiving the treatment over the next four years.
MPs emphasised that these medications, which include Mounjaro (tirzepatide), could play a crucial role in managing obesity and reducing associated health complications, thereby easing long-term burdens on the health service. The committee's report underscored that the cost-effectiveness of these drugs, which are administered via injection, merits wider adoption.
The current guidance from the National Institute for Health and Care Excellence (NICE) stipulates that Mounjaro is suitable for adults with a Body Mass Index (BMI) of 35 and above, or 30 and above if they also have at least one weight-related condition. Patients must also be enrolled in a specialist weight management service.
Despite the parliamentary committee's recommendations, there are significant capacity challenges within these specialist services, which are already struggling to meet existing demand. Expanding access to weight-loss jabs would necessitate a considerable uplift in staffing and resources for these clinics across the country.
